Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells $140,994.86 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Andrew Hollman Meyer sold 3,334 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $42.29, for a total transaction of $140,994.86. Following the transaction, the insider now directly owns 82,139 shares of the company’s stock, valued at $3,473,658.31. The trade was a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Andrew Hollman Meyer also recently made the following trade(s):

• On Thursday, January 2nd, Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock. The shares were sold at an average price of $54.88, for a total transaction of $731,769.92.

Janux Therapeutics Price Performance

NASDAQ JANX opened at $40.68 on Friday. The company’s 50 day simple moving average is $51.18 and its 200 day simple moving average is $48.34. Janux Therapeutics, Inc. has a 12 month low of $7.81 and a 12 month high of $71.71. The company has a market capitalization of $2.13 billion, a P/E ratio of -34.77 and a beta of 3.16.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The firm had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. The business’s quarterly revenue was down 82.6% compared to the same quarter last year. On average, analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analysts Set New Price Targets

JANX has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $200.00 price target on shares of Janux Therapeutics in a research note on Wednesday, December 11th. Stifel Nicolaus upped their price target on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Leerink Partners upped their price target on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 3rd. HC Wainwright upped their price target on shares of Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Finally, Lifesci Capital raised shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $89.90.

Institutional Investors Weigh In On Janux Therapeutics

Large investors have recently made changes to their positions in the company. Plato Investment Management Ltd raised its holdings in shares of Janux Therapeutics by 18.7% during the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after acquiring an additional 187 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after acquiring an additional 339 shares during the period. Avanza Fonder AB acquired a new stake in shares of Janux Therapeutics during the fourth quarter valued at approximately $139,000. AQR Capital Management LLC acquired a new stake in shares of Janux Therapeutics during the second quarter valued at approximately $215,000. Finally, Chicago Capital LLC acquired a new stake in shares of Janux Therapeutics during the fourth quarter valued at approximately $230,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.